|
|||||
|
|
| HLA-A^＊0201限制性AFP抗原决定簇肽特异性肝癌疫苗的制备 | |
| 引用本文： | 刘扬,陆崇德,吴孟超.HLA-A^＊0201限制性AFP抗原决定簇肽特异性肝癌疫苗的制备[J].同济大学学报(医学版),2009,30(6):30-33. |
| 作者姓名： | 刘扬 陆崇德 吴孟超 |
| 作者单位： | 1. 同济大学附属第十人民医院肝胆外科,上海,200072 2. 上海东方肝胆外科医院肿瘤综合治疗科,上海,200438 3. 美国匹兹堡大学肿瘤研究所,外科学和免疫学组 |
| 基金项目： | 上海市"浦江人才计划"资助项目 |
| 摘 要： | 目的探讨人HLA-A^＊0201限制性AFP抗原决定簇肽（含MHC—I类分子HLA-A^＊0201）作为原发性肝癌特异性抗原制备肝癌肿瘤疫苗的可行性。方法应用14佃AFP抗原决定簇肽片段分别体外脉冲刺激健康人血液树突状细胞（DC），将DC与自体T淋巴细胞共同培养并扩增其数量，使AFP抗原决定簇肽导入CD8’阳性T淋巴细胞（CD8^＋-CTL）并对表达相应AFP抗原决定簇肽的K562／A2．1细胞（人慢性髓原性白血病细胞株K562转染人HLA-A^＊0201基因）产生特异性杀伤并释放gamma-干扰素（ELISPOT测定）。结果有4个AFP抗原决定簇肽对表达相应AFP抗原决定簇肽的K562／A2．1细胞杀伤能力较强，称之为免疫决定簇肽（Immunodominant）；另有10个AFP抗原决定簇肽对表达相应AFP抗原决定簇肽的K562／A2．1细胞杀伤能力较弱，称之为亚免疫决定簇肽（Subdominant）。结论AFP抗原决定簇肽可以作为肝癌特异性抗原制备肝癌肿瘤疫苗，K562／A2．1细胞可以作为有效的抗原提呈细胞（APC）用于实验研究。 |
| 关 键 词： | 肿瘤 肝细胞 肝癌疫苗 甲胎蛋白类 |
Preparing for tumor vaccines of human HLA-A*0201-restricted AFP epitope peptides |
|
| LIU Yang,LU Chong-de,WU Meng-chao,Lisa H.Butterfield.Preparing for tumor vaccines of human HLA-A*0201-restricted AFP epitope peptides[J].Journal of Tongji University(Medical Science),2009,30(6):30-33. | |
| Authors: | LIU Yang LU Chong-de WU Meng-chao Lisa HButterfield |
| Institution: | LIU Yang , LU Chong-de, WU Meng-chao, Lisa H. Butterfield ( 1. Hepatobiliary Surgery Division, Tenth People＇ s Hospital, Tongji University, Shanghai 200072, China; 2. Dept. of Combined Therapy of Tumour, East Hepatobiliary Surgery Hospital, Shanghai 200438, China; 3. Dept. of Surgery and Immunology, Cancer Institute of Pittsburgh University, Pittsburgh, Pennsylvania, USA) |
| Abstract: | Objective To study the possibility of using HLA-A^＊0201-restricted peptides from human AFP as specific antigen of primary liver cancer for tumor vaccines development. Methods Drentritic cells （DC） were respectively pulsed with 14 restricted peptides, mixed with T lymphocytes for proliferation in cocultivation, followed by transduction of AFP peptides into CD8-positive T cells （ CD8^＋ -CTL） which can kill K562/A 2.1 cells expressing HLA-A^＊0201-restricted peptides of AFP and release gamma-IFN （ ELISPOT assay）. Results Four HLA-A^＊0201-restricted peptides of AFP were more potent in killing K562/A 2. 1 cells, hence were named as Immunodominants; while other 10 AFP peptides with less potency were called Immuno-Subdominants. Conclusion HLA-A^＊0201-restricted peptides of AFP may function as specific antigen to prepare liver tumor vaccines, and K562/A 2.1 can be effective antigen presentation cells （APC） in experimental research. |
| Keywords: | carcinoma hepatocellular liver cancer vaccine alpha-fetoprotein |
| 本文献已被 维普 万方数据 等数据库收录！ | |